Cidara Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2015 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cidara Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q2 2024.
  • Cidara Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 261 %, a 99.2% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 261 -31.2K -99.2% Jun 30, 2024
Q1 2024 -956 +315 +24.8% Mar 31, 2024
Q4 2023 8.13K +8.77K Dec 31, 2023
Q3 2023 -9.43K -7.33K -349% Sep 30, 2023
Q2 2023 31.4K +33.6K Jun 30, 2023
Q1 2023 -1.27K -2.16K -243% Mar 31, 2023
Q4 2022 -636 -1.33K -191% Dec 31, 2022
Q3 2022 -2.1K -2.84K -383% Sep 30, 2022
Q2 2022 -2.16K -2.48K -781% Jun 30, 2022
Q1 2022 886 +685 +340% Mar 31, 2022
Q4 2021 697 +589 +545% Dec 31, 2021
Q3 2021 743 +664 +846% Sep 30, 2021
Q2 2021 318 +248 +358% Jun 30, 2021
Q1 2021 201 +135 +204% Mar 31, 2021
Q4 2020 108 +43.8 +68.2% Dec 31, 2020
Q3 2020 78.6 +27.9 +55% Sep 30, 2020
Q2 2020 69.4 +28.7 +70.7% Jun 30, 2020
Q1 2020 66.3 +31.7 +91.7% Mar 31, 2020
Q4 2019 64.2 +31 +93.4% Dec 31, 2019
Q3 2019 50.7 +17.8 +54.2% Sep 30, 2019
Q2 2019 40.7 +7.66 +23.2% Jun 30, 2019
Q1 2019 34.6 +0.69 +2.04% Mar 31, 2019
Q4 2018 33.2 +3.79 +12.9% Dec 31, 2018
Q3 2018 32.9 +6.67 +25.5% Sep 30, 2018
Q2 2018 33 +11.7 +55% Jun 30, 2018
Q1 2018 33.9 +18.7 +123% Mar 31, 2018
Q4 2017 29.4 +18.8 +176% Dec 31, 2017
Q3 2017 26.2 +19.6 +295% Sep 30, 2017
Q2 2017 21.3 +16.3 +327% Jun 30, 2017
Q1 2017 15.2 +11.1 +272% Mar 31, 2017
Q4 2016 10.7 +5.23 +96.4% Dec 31, 2016
Q3 2016 6.64 -0.48 -6.75% Sep 30, 2016
Q2 2016 4.99 Jun 30, 2016
Q1 2016 4.08 Mar 31, 2016
Q4 2015 5.43 Dec 31, 2015
Q3 2015 7.11 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.